Youcare Pharmaceutical Group Future Growth
Future criteria checks 3/6
Youcare Pharmaceutical Group is forecast to grow earnings and revenue by 41.9% and 11.7% per annum respectively. EPS is expected to grow by 41.9% per annum. Return on equity is forecast to be 10.1% in 3 years.
Key information
41.9%
Earnings growth rate
41.9%
EPS growth rate
| Pharmaceuticals earnings growth | 18.8% |
| Revenue growth rate | 11.7% |
| Future return on equity | 10.1% |
| Analyst coverage | Low |
| Last updated | 31 Aug 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 5,306 | 459 | N/A | 656 | 2 |
| 12/31/2025 | 4,735 | 381 | N/A | 518 | 2 |
| 12/31/2024 | 4,267 | 301 | N/A | 346 | 2 |
| 6/30/2024 | 3,946 | 96 | 116 | 540 | N/A |
| 3/31/2024 | 4,036 | 169 | 232 | 714 | N/A |
| 12/31/2023 | 4,196 | 185 | 288 | 785 | N/A |
| 9/30/2023 | 3,998 | 152 | -164 | 393 | N/A |
| 6/30/2023 | 4,813 | 402 | -19 | 494 | N/A |
| 3/31/2023 | 4,770 | 357 | -350 | 129 | N/A |
| 12/31/2022 | 4,542 | 335 | -669 | -121 | N/A |
| 9/30/2022 | 5,123 | 507 | -299 | 212 | N/A |
| 6/30/2022 | 4,763 | 473 | -229 | 218 | N/A |
| 3/31/2022 | 4,987 | 539 | 138 | 490 | N/A |
| 12/31/2021 | 4,966 | 545 | 315 | 515 | N/A |
| 9/30/2021 | 4,879 | 562 | 550 | 702 | N/A |
| 6/30/2021 | 4,789 | 523 | 591 | 735 | N/A |
| 3/31/2021 | 4,481 | 476 | 509 | 638 | N/A |
| 12/31/2020 | 4,339 | 442 | 571 | 698 | N/A |
| 9/30/2020 | 4,096 | 358 | 412 | 498 | N/A |
| 12/31/2019 | 4,288 | 285 | 177 | 325 | N/A |
| 12/31/2018 | 3,983 | 268 | 19 | 193 | N/A |
| 12/31/2017 | 2,700 | 162 | N/A | 215 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 688658's forecast earnings growth (41.9% per year) is above the savings rate (2.9%).
Earnings vs Market: 688658's earnings (41.9% per year) are forecast to grow faster than the CN market (22.9% per year).
High Growth Earnings: 688658's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 688658's revenue (11.7% per year) is forecast to grow slower than the CN market (13.1% per year).
High Growth Revenue: 688658's revenue (11.7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 688658's Return on Equity is forecast to be low in 3 years time (10.1%).